Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Quanbo Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9554-063X; OpenAlex author ID A5044932847. Sources: OpenAlex.

Their work

Papers
39 (first author 7, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 6 papers · 2016: 1 paper · 2017: 3 papers · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 5 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 39

  1. circFOXP1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Regulating EREG/MAPK/ERK Axis. Co-author DOI 10.1111/jcmm.71230↗
  2. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer. Co-author DOI 10.1038/s41418-025-01464-0↗
  3. N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-025-03362-2↗
  4. Nudt21-mediated alternative polyadenylation of MZT1 3'UTR contributes to pancreatic cancer progression. Last author DOI 10.1016/j.isci.2024.108822↗
  5. Tumour-associated macrophages and Schwann cells promote perineural invasion via paracrine loop in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-023-02539-w↗
  6. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  7. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  8. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  9. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  10. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  11. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. Co-author DOI 10.1016/j.canlet.2022.215836↗
  12. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in … Co-author DOI 10.1016/j.canlet.2022.215859↗
  13. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  14. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Last author DOI 10.1038/s41388-022-02253-6↗
  15. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. Co-author DOI 10.1186/s13046-021-02237-6↗
  16. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03420-5↗
  17. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and A… Last author DOI 10.1038/s41419-021-03574-2↗
  18. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Last author DOI 10.18632/aging.202922↗
  19. Seven-gene signature on tumor microenvironment for predicting the prognosis of patients with pancreatic cancer. Co-author DOI 10.21037/gs-21-28↗
  20. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. First author DOI 10.1186/s12943-020-01196-4↗
  21. Tumor-neuroglia interaction promotes pancreatic cancer metastasis. Last author DOI 10.7150/thno.42440↗
  22. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗
  23. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41419-017-0052-1↗
  24. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41419-018-0486-0↗
  25. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-018-1104-x↗
  26. Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway. Co-author DOI 10.3892/ol.2018.8870↗
  27. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Co-author DOI 10.1016/j.canlet.2017.09.019↗
  28. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗
  29. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. First author DOI 10.3892/ol.2017.5717↗
  30. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗
  31. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00125-014-3481-8↗
  32. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Co-author DOI 10.1186/s12967-015-0442-z↗
  33. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-015-0490-4↗
  34. Metabolic phenotypes in pancreatic cancer. First author DOI 10.1371/journal.pone.0115153↗
  35. Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Co-author DOI 10.18632/oncotarget.5150↗
  36. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Co-author DOI 10.18632/oncotarget.5533↗
  37. Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs insulin secretion function of β-cell. Co-author DOI 10.1186/1479-5876-12-92↗
  38. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. First author DOI 10.1007/s10552-012-0005-z↗
  39. Pancreatic stellate cells promotes the perineural invasion in pancreatic cancer. First author DOI 10.1016/j.mehy.2012.03.017↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rufu Chen · 20 shared papers, 2012–2025 · strength 1.87
  2. Shangyou Zheng · 19 shared papers, 2015–2022 · strength 1.69
  3. Zhiqiang Fu · 18 shared papers, 2014–2025 · strength 1.47
  4. Leyi Huang · 7 shared papers, 2020–2026 · strength 1.35
  5. Huilin Ye · 17 shared papers, 2014–2022 · strength 1.31
  6. Rufu Chen · 10 shared papers, 2012–2024 · strength 1.20
  7. Jian Zheng · 6 shared papers, 2023–2025 · strength 0.91
  8. Lingxing Zeng · 6 shared papers, 2023–2025 · strength 0.91
  9. Xudong Huang · 6 shared papers, 2023–2025 · strength 0.91
  10. Jialiang Zhang · 6 shared papers, 2023–2025 · strength 0.91
  11. Dongxin Lin · 6 shared papers, 2023–2025 · strength 0.91
  12. Zhihua Li · 10 shared papers, 2012–2022 · strength 0.90
  13. Guolin Li · 9 shared papers, 2016–2022 · strength 0.81
  14. Yimin Liu · 12 shared papers, 2015–2022 · strength 0.79
  15. Lusheng Wei · 8 shared papers, 2017–2022 · strength 0.77
  16. Shaoping Zhang · 5 shared papers, 2023–2024 · strength 0.72
  17. Rihua He · 3 shared papers, 2022–2026 · strength 0.67
  18. Chonghui Hu · 5 shared papers, 2019–2022 · strength 0.67
  19. Xiaohui Zhao · 10 shared papers, 2015–2022 · strength 0.66
  20. Rui Li · 4 shared papers, 2023–2024 · strength 0.58
  21. Jiachun Su · 4 shared papers, 2023 · strength 0.56
  22. Changhao Chen · 5 shared papers, 2017–2022 · strength 0.51
  23. Ziming Chen · 3 shared papers, 2023–2025 · strength 0.49
  24. Xiaowei He · 3 shared papers, 2023–2025 · strength 0.49
  25. Zilan Xu · 3 shared papers, 2023–2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.